Krystal Biotech, Inc. $KRYS Shares Sold by Frazier Life Sciences Management L.P.

Key Points

• Frazier Life Sciences Management L.P. reduced its stake in Krystal Biotech by 12.7%, selling 100,000 shares, which leaves them with 688,460 shares, accounting for about 5.7% of their investment portfolio.
• Insider Suma Krishnan sold 13,435 shares at an average price of $150.30, totaling over $2 million, while still retaining a substantial ownership of 1,443,276 shares.
• A number of analysts have updated their price targets for Krystal Biotech, with the consensus price target currently at $210.38, indicating a "Moderate Buy" rating among analysts.

Frazier Life Sciences Management L.P. lessened its stake in shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 12.7% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 688,460 shares of the company's stock after selling 100,000 shares during the quarter. Krystal Biotech accounts for about 5.7% of Frazier Life Sciences Management L.P.'s investment portfolio, making the stock its 6th largest position. Frazier Life Sciences Management L.P. owned 2.38% of Krystal Biotech worth $124,129,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also recently bought and sold shares of the stock. Crossmark Global Holdings Inc. lifted its holdings in shares of Krystal Biotech by 2.7% during the first quarter. Crossmark Global Holdings Inc. now owns 2,370 shares of the company's stock valued at $427,000 after acquiring an additional 63 shares during the period. Xponance Inc. lifted its holdings in Krystal Biotech by 4.9% during the 1st quarter. Xponance Inc. now owns 1,873 shares of the company's stock valued at $338,000 after purchasing an additional 88 shares during the last quarter. Sound View Wealth Advisors Group LLC lifted its holdings in Krystal Biotech by 6.7% during the 1st quarter. Sound View Wealth Advisors Group LLC now owns 1,515 shares of the company's stock valued at $273,000 after purchasing an additional 95 shares during the last quarter. New York State Teachers Retirement System boosted its position in Krystal Biotech by 0.6% in the first quarter. New York State Teachers Retirement System now owns 15,979 shares of the company's stock valued at $2,881,000 after buying an additional 100 shares in the last quarter. Finally, Fifth Third Bancorp grew its stake in Krystal Biotech by 159.1% during the first quarter. Fifth Third Bancorp now owns 171 shares of the company's stock worth $31,000 after buying an additional 105 shares during the last quarter. 86.29% of the stock is currently owned by institutional investors.

Insider Activity

In other news, insider Suma Krishnan sold 13,435 shares of Krystal Biotech stock in a transaction that occurred on Monday, July 14th. The shares were sold at an average price of $150.30, for a total transaction of $2,019,280.50. Following the completion of the sale, the insider owned 1,443,276 shares in the company, valued at $216,924,382.80. The trade was a 0.92% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Over the last 90 days, insiders have sold 49,800 shares of company stock valued at $7,487,943. 13.70% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on the stock. Guggenheim cut their target price on shares of Krystal Biotech from $195.00 to $189.00 and set a "buy" rating for the company in a research note on Wednesday, May 7th. Bank of America dropped their price target on Krystal Biotech from $193.00 to $192.00 and set a "buy" rating for the company in a report on Tuesday, July 22nd. HC Wainwright reissued a "buy" rating and issued a $240.00 price objective on shares of Krystal Biotech in a research note on Friday, August 22nd. Citigroup restated a "neutral" rating and issued a $166.00 target price (down from $176.00) on shares of Krystal Biotech in a research note on Tuesday, August 5th. Finally, Chardan Capital cut their price target on Krystal Biotech from $219.00 to $216.00 and set a "buy" rating for the company in a report on Friday, August 22nd. Seven investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $210.38.

Krystal Biotech Stock Performance

NASDAQ KRYS opened at $147.70 on Tuesday. The stock has a fifty day moving average of $146.02 and a 200-day moving average of $154.27. The stock has a market capitalization of $4.27 billion, a P/E ratio of 30.02 and a beta of 0.66. Krystal Biotech, Inc. has a 52 week low of $122.80 and a 52 week high of $207.84.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last issued its quarterly earnings results on Monday, August 4th. The company reported $1.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.08 by $0.21. The business had revenue of $96.04 million for the quarter, compared to analyst estimates of $95.42 million. Krystal Biotech had a return on equity of 15.21% and a net margin of 40.85%. Equities research analysts forecast that Krystal Biotech, Inc. will post 6.14 earnings per share for the current fiscal year.

Krystal Biotech Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.